Cabozantinib, a receptor tyrosine kinase inhibitor, shows potent anti-tumor effects in animal and human studies through inhibition of receptor tyrosine kinase phosphorylation, particularly MET and VEGFR2 (5). This evidence concerns the gene NTRK1 and neoplasm.